首页> 美国政府科技报告 >High-Content FRET-FLIM Screening in Inhibitors of Oncogenic Transcription by C-Myc in Breast Cancer
【24h】

High-Content FRET-FLIM Screening in Inhibitors of Oncogenic Transcription by C-Myc in Breast Cancer

机译:高密度FRET-FLIm筛选C-myc在乳腺癌中的致癌转录抑制剂

获取原文

摘要

To develop a novel high content screen to identify inhibitors that block Myc:TRRAP interaction, in the first year of this project we constructed several fluorescent fusion protein constructs of Myc and TRRAP, and evaluated their ability to bind and engage in fluorescence energy transfer (FRET) in vivo. All year-one tasks were completed in the first year of the grant. During the second year we discovered that expression of Myc-CFP was toxic to some cells and in other cells the Myc-CFP did not show the expected blue fluorescence. Due to the short half-life of Myc most of the CFP-Myc proteins were turning over before the CFP matured and became fluorescent. To overcome this unexpected issue, we introduced a mutation (T58A) to increase the stability of the CFP-Myc fusion protein and we evaluated additional cell lines, as well as new expression constructs. Conditions were identified in which sufficient CFP-Myc folded correctly and became fluorescent. To define Myc:TRRAP co-regulated target genes we established a Myc-dependent transformation system in the MCF10A cells and conducted Myc-specific ChIP-on-chip in these cells with and without ectopic Myc expression. Expression profiling of these cells was also conducted and data analysis revealed the subset of genes whose promoter was bound and regulated by Myc. During validation of the compound screen we discovered an engineering problem with the FRET-FLIM screening device that prevented the analysis of large numbers of samples. To rectify this we designed and built a pulse stretcher for the FLIM-Opera screening instrument.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号